Company intelligence / Profile preview
Zelluna
Oslo, Norwayzelluna.com ↗
- Ownership
- Public · ZLNA
- Development stage
- Other
01
Overview
Zelluna's lead asset, ZI-MA4-1, is an off-the-shelf TCR-NK cell therapy targeting MAGE-A4 and is in preclinical development. They have established a scalable GMP manufacturing process and expect to file for clinical entry (likely a CTA/IND) in the second half of 2025 targeting multiple solid tumor indications. No clinical data are yet reported as of August 2025.[4][5][1]
- Therapeutic areas
- Oncology
- Modalities
- T cell receptor engineered T cell therapyNK cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Catalent
04
Financials
- Market cap
- $53.1M
- Total revenue
- $0
- Enterprise value
- $44M
Beyond the preview
Go deeper on Zelluna.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zelluna.